Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.31 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4645608 | 0.79 | CA2 (0.50) | CA2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL1416183 | 0.76 | CES2 (0.38) | ALDH1A1CA2 | |
| SCHEMBL23569835 | 0.76 | CA2 (0.39) | KITCA2CCNE1CDK2CDK5 | |
| SCHEMBL1127299 | 0.74 | DAO (0.39) | ALDH1A1KITCA2 | |
| SCHEMBL23568555 | 0.74 | TRPV4 (0.38) | TRPV4 | |
| SCHEMBL15881134 | 0.71 | CA2 (0.39) | CA2 | |
| SCHEMBL27174852 | 0.71 | CA2 (0.46) | CA2 | |
| SCHEMBL3017949 | 0.70 | GAB1 (0.50) | ALDH1A1CA2GAB1 | |
| SCHEMBL16237378 | 0.70 | CA2 (0.46) | CA2 | |
| SCHEMBL21963394 | 0.70 | CA2 (0.33) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105143188-B | Novel sulfonamide TRPA1 receptor antagonists | 阿里奥制药有限公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-2964615-A1 | NOVEL SULFONAMIDE TRPA1 RECEPTOR ANTAGONISTS | Ario Pharma Limited (GB) | 2016-01-13 | — | — | EP | disclosed |
| CN-105143188-A | Novel sulfonamide trpa1 receptor antagonists | PHARMESTE S R L IN LIQUIDATION | 2015-12-09 | — | — | CN | disclosed |
| WO-2014135617-A1 | NOVEL SULFONAMIDE TRPA1 RECEPTOR ANTAGONISTS | PHARMESTE S.R.L. IN LIQUIDATION (IT) | 2014-09-12 | — | — | WO | disclosed |
| CN-101516852-B | Quinoline derivatives with 5-ht-binding properties | HOFFMANN LA ROCHE | 2011-11-16 | — | — | CN | disclosed |
| US-7825253-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2076495-B1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | HOFFMANN LA ROCHE (CH) | 2010-08-18 | — | — | EP | disclosed |
| CN-101516852-A | Quinoline derivatives with 5-HT-binding properties | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-2076495-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008037626-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | AR, ADRA2C, RCC2 | ALDH1A1 872/4885CYP3A4 339/4885MAPK1 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.